Crispr Therapeutics AG (CRSP) at a glance

Crispr Therapeutics AG (CRSP) is a mid-cap Healthcare company. It trades at $51.8, with a 0% profit margin and revenue growth of 68.6%. It does not pay a dividend. Vestovix scores it 52/100 overall. Its strongest dimension is Growth (92/100) and its weakest is Safety (24/100). It carries above-market volatility, so expect larger swings.

Price

$51.80

Market cap

$4.90B

P/E ratio

n/a

Dividend yield

None

Beta

1.70

52-week range

$44.12 to $78.48